SAN DIEGO, Feb. 17, 2016 /PRNewswire/ -- ViaCyte, Inc., a privately-held regenerative medicine company with the first pluripotent stem cell-derived islet replacement therapy for the treatment of diabetes in clinical-stage development, today announced three presentations at upcoming healthcare events.
Details of the presentations are as follows:
|
Event: |
Regenerative Medicine: Transitioning Therapeutics from Cells to the Clinic |
|
Title: |
Development of Stem-Cell Derived, Macroencapsulated Islet Replacement for Type 1 Diabetes |
|
Speaker: |
Dr. Thomas Schulz, Director, ES Cell Technology |
|
Date/Time: |
February 22, 2:35 p.m. EST |
|
Location: |
New York Academy of Sciences Conference Center, New York, NY |
|
Event: |
The 2nd Saudi International Biotechnologies Conference 2016 |
|
Title: |
Chasing a Cure for Type 1 Diabetes: The Development of a Stem Cell Derived Islet Replacement Therapy |
|
Speaker: |
Dr. Paul Laikind, President and CEO |
|
Date/Time: |
February 23, 9:15 a.m. AST |
|
Location: |
KACST Headquarters, Conference Hall, Riyadh, Saudi Arabia |
|
Event: |
American Society of Transplantation: Pipeline Presenters |
|
Speaker: |
Dr. Kevin D'Amour, Vice President, Research and CSO |
|
Date/Time: |
February 25, 11:00 a.m. MST |
|
Location: |
Arizona Biltmore, Phoenix, Arizona |
ViaCyte's VC-01™ product candidate, a first-in-class cell replacement therapy for the treatment of type 1 diabetes, is currently being evaluated in a Phase 1/2 trial called STEP ONE, or Safety, Tolerability, and Efficacy of VC-01 Combination Product in Type One Diabetes. More info on the clinical trial is here: https://clinicaltrials.gov/ct2/show/NCT02239354.
For more information about ViaCyte's participation in industry events, please visit: http://viacyte.com/news-events-2/viactye-events/
About ViaCyte
ViaCyte is a privately-held regenerative medicine company focused on developing a novel cell replacement therapy for the treatment of diabetes. ViaCyte is conducting a Phase 1/2 clinical trial of the Company's lead VC-01 product candidate in patients with type 1 diabetes who have minimal to no insulin-producing beta cell function. ViaCyte's VC-01 combination product candidate is based on the production of pancreatic progenitor cells derived from human pluripotent stem cells. These progenitor cells are implanted in a durable and retrievable encapsulation device. Once implanted and matured, these cells are designed to secrete insulin and other regulatory factors in response to blood glucose levels. The VC-01 product candidate is being developed as a potential long-term diabetes treatment with the goal of reducing the risk of hypoglycemia and diabetes-related complications without requiring long-term immune suppression.
ViaCyte is headquartered in San Diego, California with additional operations in Athens, Georgia. The Company is funded in part by the California Institute for Regenerative Medicine (CIRM) and JDRF.
For more information please visit www.viacyte.com. Connect with ViaCyte here: www.twitter.com/viacyte and www.facebook.com/viacyte.
Logo - http://photos.prnewswire.com/prnh/20121026/LA00871LOGO-a
SOURCE ViaCyte, Inc.